Q-omics provides the consensus-scored MIR3663HG profile across patient tissues and cancer cell-line models. MIR3663HG expression is associated with patient survival in 10 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, MIR3663HG is differentially expressed in 1, with the highest sampling consensus in LUSC. Additionally, MIR3663HG RNA expression shows 6,184 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight UCEC, LUSC, and STAD as cancer lineages where MIR3663HG shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR3663HG — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR3663HG survival associations across molecular data types. MIR3663HG RNA expression shows survival associations in the most cancer types (10). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR3663HG RNA expression–survival associations across cancer types. High MIR3663HG expression shows unfavorable associations in UCEC, STAD, PAAD, KIRP, KIRC and COAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify UCEC as the clearest survival context for MIR3663HG RNA expression.
This table summarizes MIR3663HG tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 1. The strongest signals are observed in LUSC for RNA.
This table ranks reproducible tumor–normal expression differences for MIR3663HG. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR3663HG shows higher tumor expression in LUSC. The LUSC box plot shows higher MIR3663HG RNA expression in tumor versus normal tissue (log2 FC = +0.020, t-test p = .009).
This table shows molecular features associated with MIR3663HG in patient tissues and cancer cell lines. In patient samples, MIR3663HG shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
